BiologicalDrug
Volagidemab clinical trials
Also written REMD-477.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 6
REMD Biotherapeutics, Inc. (4) · University of California, San Diego (3) · Duke University (2) · The University of Texas Health Science Center at San Antonio (1)
Studies
Open first, then newest update. How each study uses volagidemab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Effects of GRA in Patients With Type 1Active, not recruitingPhase 2University of California, San DiegoNCT04779645Written as REMD-477
- Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With VolagidemabCompletedPhase 1REMD Biotherapeutics, Inc.NCT06272695Written as Volagidemab
- Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DMCompletedEarly Phase 1The University of Texas Health Science Center at San AntonioNCT05093517Written as REMD-477
- Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusCompletedPhase 2REMD Biotherapeutics, Inc.NCT03117998Written as REMD-477
- Combination GRA and SGLT-2i Treatment in Type 1 DiabetesCompletedPhase 1/2University of California, San DiegoNCT04545411Written as REMD-477
- Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)TerminatedPhase 1Duke UniversityNCT04330625Written as REMD-477
- Metabolic Pathways of GRA in Patients With Type 1 DiabetesCompletedPhase 1/2University of California, San DiegoNCT03919617Written as REMD-477
- A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to CopanlisibTerminatedPhase 1Duke UniversityNCT04253223Written as REMD-477
- Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes MellitusCompletedPhase 1/2REMD Biotherapeutics, Inc.NCT02455011Written as REMD-477
- Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusCompletedPhase 1REMD Biotherapeutics, Inc.NCT02715193Written as REMD-477
Codes
What other systems call volagidemab · ClinicalTrials.gg INT001038
- MeSH (NLM) C000629677volagidemabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 77JYS6UZ0MVOLAGIDEMABConfirmed FDA, NLM, Wikidata
- Wikidata Q123857875volagidemabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167005VolagidemabOne source FDA
- DrugBank DB16421One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629677 | volagidemab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 77JYS6UZ0M | VOLAGIDEMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123857875 | volagidemab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167005 | Volagidemab | One source FDA |
| DrugBank | DB16421 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.